Your deck may explain the science. It may still fail the commercial screen.
Investors and pharma teams do not want to reverse-engineer the business case from the mechanism slide. They need to see who the first real buyer is, why this asset fits a portfolio, what slows adoption, and what proof is still missing.
Read this if your team is preparing outreach, raising around the next milestone, or hearing polite interest without a clear next meeting.
If two boxes are weak, stop editing the deck.
Run the checklist first. If the gaps are real, the next move is a Strategy Diagnostic: a written map of the commercial case, buyer language, proof gaps, and outreach route.
A biotech is commercially ready for investor or pharma outreach when a non-scientific buyer can answer five questions fast: who is the first commercial patient group, which partner has a reason to care, what blocks adoption, what proof is missing, and why the timing matters now.
Total biopharma deal value in 2024, according to McKinsey's 2025 dealmaking analysis.
Pharma alliances in 2024, worth $144 billion in potential biobucks, cited by DCAT from EY research.
Small biotech companies with less than one year of cash runway in EY's 2025 biotech outlook.
Use this when the science is not the problem anymore
Most biotech teams do not lose serious conversations because the science deck is ugly. They lose them because the commercial path is slow to understand. The reader has to ask basic questions: which patient group, which partner, which reimbursement risk, which milestone, which proof?
That friction matters. A pharma business development lead can like the science and still defer the conversation if the business case takes too much work to route internally. An investor can believe the mechanism and still pass if the next financing story does not connect to a credible partner or market-access path.
This checklist supports the existing SF Marketing Agency biotech cluster: investor narrative for early biotech, biotech commercial partnerships, and scientific credibility versus commercial credibility.
Commercial readiness checklist
Do not treat this as a content exercise. These are decision filters. If the answer is fuzzy, outreach will make the weakness visible.
Can a buyer see the first commercial patient group?
Name the diagnosed population, the likely label-sized subset, the severity of the problem, and why this group is worth commercial attention now.
Weak signal: the deck uses a broad TAM number but never shows the first reachable patient segment.
Can pharma see why this asset belongs in its portfolio?
Build a shortlist around therapeutic area focus, portfolio gaps, sourcing patterns, and the internal sponsor who would care.
Weak signal: the outreach list is broad because the asset story has not been matched to specific partner priorities.
Can the story explain what will slow adoption?
Show the reimbursement barrier, prescriber behavior change, patient identification problem, and health economics proof still missing.
Weak signal: the story jumps from approval to revenue without showing payer and provider friction.
Can the next milestone change the asset's value?
Define the milestone, what it proves, who needs to hear the story before it lands, and why timing matters before runway pressure is obvious.
Weak signal: outreach starts only when the company needs cash, not when the asset becomes easier to evaluate.
Why this matters in the current biotech market
The partnership market is active. McKinsey's biopharma dealmaking analysis reports total deal value of $191 billion in 2024. It also reports that more than 70 percent of new molecular entity revenues at large pharma companies have come from externally sourced products since 2018.
McKinsey, Pulse Check: Key Trends Shaping Biopharma Dealmaking in 2025
DCAT's summary of EY Beyond Borders research reports 220 pharma alliances in 2024, worth $144 billion in potential biobucks. The capital and appetite are there. The weaker signal is not demand. The weaker signal is whether a biotech can be evaluated quickly.
DCAT Value Chain Insights, citing EY Beyond Borders 2025
Runway pressure raises the stakes. EY reports that 39 percent of small biotech companies had less than one year of cash runway in 2025. A company that waits until that pressure is obvious has less control over timing, terms, and buyer attention.
EY Life Sciences / Biotech Outlook
What buyers and partners ask when the science is promising
A serious investor or pharma team is not only asking whether the mechanism is credible. They are asking whether the company can explain the commercial route without making them do the translation work.
The questions that expose the gap
- Which patient group is commercially addressable, not only clinically interesting?
- Which existing standard of care will the asset displace, avoid, or sit beside?
- Which pharma portfolio gap makes this asset worth a second look?
- What market-access barrier will slow adoption after approval?
- What milestone changes the asset's value, and who needs to hear the story before that point?
- What proof belongs in the first outreach packet instead of the third call?